CMP: ₹3,377.35
We expect Acutaas Chemicals to deliver sustained earnings growth driven by a strong 28 per cent CAGR in the CDMO business over FY26–30E, and incremental contribution from newer businesses such as electrolyte additives, semiconductors and electronic chemicals. Our calculations suggest Daro-volumes could grow about 3x over FY26–30E to about 160 tonne by FY30E supported by the expanding Nubeqa patient base following successful outcomes of ARASTEP and DASL-HiCaP trial. This is expected to translate to Daro-V revenue of about ₹1,700 crore by FY30E, which would be the key growth driver in the CDMO business.
We are also building in about 45 per cent CAGR for Specialty Chemicals’ revenue — increasing from ₹160 crore in FY26 to ₹730 crore by FY30E — driven by the shift towards higher value semiconductor chemicals and electrolyte additives.
In Pharma Intermediates, we expect the four new CDMO molecules to scale up to ₹320 crore by FY30E while Apixaban’s anticipated Nov’26 patent expiry is expected to support growth in the legacy pharma business.
Overall, we reckon a revenue/EBITDA/PAT CAGR of 28/29/28 per cent over FY26-30E. This note marks resumption of coverage on Acutaas with a Buy and target price of ₹3,800 based on 45x Sep’28E EPS
Published on September 11, 2026
